| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10449173 | ALLERGAN | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
Nov, 2029
(6 years from now) | |
| US9259388 | ALLERGAN | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
Nov, 2029
(6 years from now) | |
| US8920392 | ALLERGAN | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
Mar, 2031
(7 years from now) | |
Gelnique is owned by Allergan.
Gelnique contains Oxybutynin Chloride.
Gelnique has a total of 3 drug patents out of which 0 drug patents have expired.
Gelnique was authorised for market use on 27 January, 2009.
Gelnique is available in gel;transdermal dosage forms.
Gelnique can be used as treatment of overactive bladder by application of oxybutynin chloride gel to skin, treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence with a single unit dose of 10% oxybutynin chloride gel.
The generics of Gelnique are possible to be released after 26 March, 2031.
Drugs and Companies using OXYBUTYNIN CHLORIDE ingredient
Market Authorisation Date: 27 January, 2009
Treatment: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence with a single unit dose of 10% oxybutynin chloride gel; Treatment of overactive bladd...
Dosage: GEL;TRANSDERMAL
GELNIQUE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic